hormone therapy

PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...

San Diego, USA | May 1, 2026 Neurocrine Biosciences has reported new two-year Phase 3 clinical data for CRENESSITY®...

TAIPEI, August 28, 2025 — Foresee Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the...